A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Castle Biosciences Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 19,000 shares of CSTL stock, worth $413,630. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,000
Previous 32,100 40.81%
Holding current value
$413,630
Previous $692,000 39.31%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$18.06 - $25.3 $236,585 - $331,430
-13,100 Reduced 40.81%
19,000 $420,000
Q4 2023

Feb 14, 2024

SELL
$12.19 - $22.43 $297,436 - $547,292
-24,400 Reduced 43.19%
32,100 $692,000
Q3 2023

Nov 14, 2023

SELL
$13.28 - $20.3 $484,720 - $740,950
-36,500 Reduced 39.25%
56,500 $954,000
Q2 2023

Aug 14, 2023

SELL
$11.66 - $26.0 $225,038 - $501,800
-19,300 Reduced 17.19%
93,000 $1.28 Million
Q1 2023

May 15, 2023

SELL
$19.47 - $28.49 $385,506 - $564,102
-19,800 Reduced 14.99%
112,300 $2.55 Million
Q4 2022

Feb 14, 2023

SELL
$18.08 - $30.0 $385,103 - $639,000
-21,300 Reduced 13.89%
132,100 $3.11 Million
Q3 2022

Nov 14, 2022

SELL
$22.51 - $34.32 $42,769 - $65,208
-1,900 Reduced 1.22%
153,400 $4 Million
Q2 2022

Aug 15, 2022

BUY
$16.0 - $45.99 $2.1 Million - $6.05 Million
131,500 Added 552.52%
155,300 $3.41 Million
Q1 2022

May 16, 2022

SELL
$33.17 - $46.98 $2.91 Million - $4.12 Million
-87,700 Reduced 78.65%
23,800 $1.07 Million
Q4 2021

Feb 14, 2022

BUY
$39.06 - $67.58 $1.24 Million - $2.14 Million
31,700 Added 39.72%
111,500 $4.78 Million
Q3 2021

Nov 15, 2021

BUY
$60.13 - $77.6 $1.74 Million - $2.25 Million
29,000 Added 57.09%
79,800 $5.31 Million
Q2 2021

Aug 16, 2021

SELL
$50.07 - $76.78 $565,791 - $867,614
-11,300 Reduced 18.2%
50,800 $3.73 Million
Q1 2021

May 17, 2021

BUY
$58.92 - $97.33 $2.18 Million - $3.6 Million
37,000 Added 147.41%
62,100 $4.25 Million
Q4 2020

Feb 16, 2021

BUY
$43.6 - $73.05 $579,880 - $971,565
13,300 Added 112.71%
25,100 $1.69 Million
Q3 2020

Nov 16, 2020

SELL
$38.47 - $52.03 $96,175 - $130,075
-2,500 Reduced 17.48%
11,800 $607,000
Q2 2020

Aug 14, 2020

BUY
$27.28 - $43.01 $21,824 - $34,408
800 Added 5.93%
14,300 $539,000
Q1 2020

May 15, 2020

SELL
$23.08 - $35.53 $20,772 - $31,977
-900 Reduced 6.25%
13,500 $402,000
Q4 2019

Feb 14, 2020

SELL
$15.74 - $35.04 $31,480 - $70,080
-2,000 Reduced 12.2%
14,400 $495,000
Q3 2019

Nov 14, 2019

BUY
$18.09 - $27.92 $296,676 - $457,888
16,400 New
16,400 $297,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $572M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.